



ODB[™] INJECTION


ACTIVE CONSTITUENT: 1 mg/mL 0ESTRADIOL BENZOATE

Time it right

To improve the precision of the onset of oestrus and maximise fertility in oestrous synchronisation programmes using an intravaginal insert containing progesterone (1.379 g/insert) in cycling cattle.

To induce oestrus and ovulation after progesterone priming with an intravaginal insert containing progesterone (1.379 g/insert) in the treatment of anoestrus in cattle.

- Enhances the precision of onset of oestrus
- Ensures a high fertility oocyte at ovulation after cessation of progesterone treatment
- Stimulation and acceleration of developing and maturing dominant follicle, and oestrus and ovulation follow
- **%** NIL meat and milk WHP



| | ODB™ | BOMEROL® |
|--|---|---|
| Active Constituent | 1mg/mL OESTRADIOL BENZOATE | 1mg/mL OESTRADIOL BENZOATE |
| Species | Cattle | Cattle |
| Route of Administration | IM Injection | IM Injection |
| Dose rate | | |
| Oestrous synchronisation program | 1mL in heifers or 2mL in adult cows at time of insertion of intravaginal insert containing progesterone | 1mL in heifers or 2mL in adult cows at time of insertion of intravaginal insert containing progesterone |
| Treatment of anoestrous | 1mL 24-48 hours after the removal of the intravaginal insert containing progesterone | 1mL 24-48 hours after the removal of the intravaginal insert containing progesterone |
| Witholding periods | | |
| Meat | Zero Days | Zero Days |
| Milk | Zero Days | Zero Days |
| | ODB™ is a trademark of Abbey Laboratories Pty Ltd | BOMEROL® is a registered trademark of Elanco Animal Health GmbH |

ODB™ INJECTION

ACTIVE CONSTITUENT: 1 mg/mL 0ESTRADIOL BENZOATE



To improve the precision of the onset of oestrus and maximise fertility in oestrous synchronisation programmes using an intravaginal insert containing progesterone (1.379 g/insert) in cycling cattle.

To induce oestrus and ovulation after progesterone priming with an intravaginal insert containing progesterone (1.379 g/insert) in the treatment of anoestrus in cattle.

DIRECTIONS FOR USE

Contraindications

Administration of high doses of oestradiol benzoate to pregnant cattle has been shown to cause abortion.

DOSAGE AND ADMINISTRATION

Inject by intramuscular injection in the anterior half of the neck.

For use in oestrous synchronisation programmes in cycling cattle: Inject 1mL in heifers or 2mL in adult cows at the time of administration of the intravaginal insert containing progesterone.

For use in the treatment of anoestrous cattle: Inject 1mL between 24 and 48 hours after the removal of the intravaginal insert containing progesterone.

General Directions MODE OF ACTION

The intramuscular injection of oestradiol benzoate at the initiation of progesterone treatment in cycling cattle (e.g. at the same time as the administration of an intravaginal insert containing progesterone) results in follicular turnover and the emergence of a new follicular wave about four days after treatment. The synchronous emergence of this new follicular wave both enhances the precision of the onset of oestrus and ensures a high fertility oocyte at ovulation after the cessation of progesterone treatment.

The intramuscular injection of oestradiol benzoate during the pro-oestrus period, induced by progesterone priming (e.g. following removal of the intravaginal insert containing progesterone) in anoestrous cattle induces the release of endogenous gonadotrophins, particularly LH. This results in both stimulation and acceleration of the developing and maturing dominant follicle, and oestrus and ovulation follow.

In addition, the administration of oestradiol during the pro-oestrus phase increases the expression of oestrus.

WITHHOLDING PERIODS

MEAT: Zero (0) days.

MILK: Zero (0) days.

FIRST AID

If poisoning occurs, contact a doctor or Poisons Information Centre, Phone Australia 131 126.

DISPOSAL

Dispose of container by wrapping with paper and putting in garbage.

STORAGE

Store below 25°C (air conditioning). Protect from light. Refrigerate open bottle, use within 7 days of opening.

Causes serious eye irritation.

May cause cancer.

May damage fertility or the unborn child.

May cause harm to breast-fed children.

Use personal protective equipment as required.

Wear eye or face protection.

Do not eat, drink or smoke when using this product.

Avoid contact during pregnancy or while nursing.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.

APVMA Approval Number: 92123/134575